SEC Form SC 13D/A filed by Clearside Biomedical Inc. (Amendment)

SEC Form SC 13D/A filed by Clearside Biomedical Inc. (Amendment)

Recent Analyst Ratings for $CLSD

$CLSD Press Releases

$CLSD Large Ownership Changes

$CLSD Leadership Updates

$CLSD Analyst Ratings

$CLSD Insider Purchases

$CLSD SEC Filings

$CLSD Insider Trading

$CLSD Market Insights

$CLSD FDA approvals

$CLSD Financials

Recent Analyst Ratings for
$CLSD

$CLSD
Press Releases

$CLSD
Large Ownership Changes

$CLSD
Leadership Updates

$CLSD
Analyst Ratings

$CLSD
Insider Purchases

$CLSD
SEC Filings

$CLSD
Insider Trading

$CLSD
Market Insights

$CLSD
FDA approvals

$CLSD
Financials

Chat with this insight

Fastest customizable press release news feed in the world

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

Live Leadership Updates

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Chardan Capital Markets initiated coverage on Clearside Biomedical with a new price target

Oppenheimer initiated coverage on Clearside Biomedical with a new price target

JMP Securities reiterated coverage on Clearside Biomedical with a new price target

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

Yerxa Benjamin R bought $10,235 worth of shares (7,813 units at $1.31), increasing direct ownership by 77% to 17,957 units (SEC Form 4)

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 10-Q filed by Clearside Biomedical Inc.

Clearside Biomedical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Clearside Biomedical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

Amendment: New insider Chong Ngai Hang Victor claimed ownership of 10,000 shares (SEC Form 3)

Live Market Insights

Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target

Why Is Clearside Biomedical Stock Gaining Today?

Clearside Biomedical shares are trading higher after Oppenheimer initiated coverage with an Outperform rating and a price target of $5.

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

Live finance-specific insights

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

1/4/23 4:15:03 PM ET

$CLSD

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CLSD alert in real time by email

SC 13D/A 1 d409538dsc13da.htm SC 13D/A SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Amendment No. 6)*

Under the Securities Exchange Act of 1934

CLEARSIDE BIOMEDICAL, INC.

(Name of Issuer)

Common Stock, $0.001 Par Value

(Title of Class of Securities)

185063 10 4

(CUSIP Number)

Clay Thorp

280 S. Mangum Street, Suite 350

Durham, North Carolina 27701

(919) 484-0730

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 15, 2022

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule l3G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 185063 10 4

Page 2 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) 20-4822068 Hatteras Venture Advisors III, LLC
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 3 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) 20-482290 Hatteras Venture Partners III, LP
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 4 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) 20-5052088 Hatteras Venture Affiliates III, LP
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 5 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) Hatteras Venture Advisors IV SBIC, LLC
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 6 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) 32-0389462 Hatteras Venture Partners IV SBIC, LP
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 7 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) 20-4822068 Hatteras Venture Advisors IV, LLC
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 8 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) 45-2827886 Hatteras Venture Partners IV, LP
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 9 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) 38-3890444 Hatteras NC Fund, LP
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 10 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) John C. Crumpler
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 11 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) Robert A. Ingram
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 12 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) Kenneth B. Lee
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 13 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) Clay B. Thorp
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

¹	Includes 16,522 shares held directly by the Reporting Person and 92,500 shares of Common Stock subject to options held by the Reporting Person that are exercisable within 60 days of December 20, 2022.

CUSIP No. 185063 10 4

Page 14 of 20


1.		Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) Douglas Reed
2.		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO – See Item 3
5.		Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable
6.		Citizenship or Place of Organization United States

CUSIP No. 185063 10 4

Page 15 of 20

This Amendment No. 6 on Schedule 13D amends the statement on Schedule 13D, dated June 7, 2016, which relates to the Common Stock, par value $0.001 per share (the “Common Stock”) of Clearside Biomedical, Inc. (the “Issuer”) which was previously amended on Schedule 13D/A, dated January 20 and April 17, 2017, March 21, 2018 and July 17 and December 4, 2019 filed by:

Hatteras Venture Advisors III, LLC (“HVA III”)

Hatteras Venture Partners III, LP (“HVP III”)

Hatteras Venture Affiliates III, LP (“HV Affiliates”)

Hatteras Venture Advisors IV SBIC, LLC (“HVA SBIC”)

Hatteras Venture Partners IV SBIC, LP (“HVP SBIC”)

Hatteras Venture Advisors IV, LLC (“HVA IV”)

Hatteras Venture Partners IV, LP (“HVP IV”)

Hatteras NC Fund, LP (“Hatteras Fund”)

John C. Crumpler

Robert A. Ingram

Kenneth B. Lee

Clay B. Thorp

Douglas Reed

(collectively, the “Reporting Persons”).

Except as expressly amended below, the Schedule 13D, dated June 7, 2016, remains in effect.

Item 5.

Interest in Securities of the Issuer.

(a)	Aggregate number and percentage beneficially owned:

HVA III — 0 or 0%

HVP III — 0 or 0%

HV Affiliates — 0 or 0%

HVA SBIC— 3,055,052 or 5.1%

HVP SBIC — 3,055,052 or 5.1%

HVA IV— 489,988 or less than 1%

HVP IV — 387,475 or less than 1%

Hatteras Fund— 102,513 or less than 1%

John C. Crumpler — 3,550,214 or 5.9%

Robert A. Ingram — 3,555,302 or 5.9%

Kenneth B. Lee — 3,550,214 or 5.9%

Clay B. Thorp — 3,654,062 or 6.1%

Douglas Reed — 3,551,432 or 5.9%

(b)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote

HVA III — 0

HVP III — 0

HV Affiliates — 0

HVA SBIC— 0

CUSIP No. 185063 10 4

Page 16 of 20

HVP SBIC — 0

HVA IV— 0

HVP IV — 0

Hatteras Fund— 0

John C. Crumpler — 5,174

Robert A. Ingram — 10,262

Kenneth B. Lee — 5,174

Clay B. Thorp — 109,022

Douglas Reed — 6,392

(iii)

Sole power to dispose or to direct the disposition of

HVA III — 0

HVP III — 0

HV Affiliates — 0

HVA SBIC— 0

HVP SBIC — 0

HVA IV— 0

HVP IV — 0

Hatteras Fund— 0

John C. Crumpler — 5,174

Robert A. Ingram — 10,262

Kenneth B. Lee — 5,174

Clay B. Thorp — 109,022

Douglas Reed — 6,392

(iv)

Shared power to dispose or to direct the disposition of

HVA III — 0

HVP III — 0

HV Affiliates — 0

HVA SBIC— 3,055,052

HVP SBIC — 3,055,052

HVA IV— 489,988

HVP IV — 387,475

Hatteras Fund— 102,513

John C. Crumpler — 3,545,040

Robert A. Ingram — 3,545,040

Kenneth B. Lee — 3,545,040

Clay B. Thorp — 3,545,040

Douglas Reed — 3,545,040

(ii)

Shared power to vote or to direct the vote

HVA III — 0

HVP III — 0

HV Affiliates — 0

HVA SBIC— 3,055,052

HVP SBIC — 3,055,052

HVA IV— 489,988

HVP IV — 387,475

Hatteras Fund— 102,513

John C. Crumpler — 3,545,040

CUSIP No. 185063 10 4

Page 17 of 20

Robert A. Ingram — 3,545,040

Kenneth B. Lee — 3,545,040

Clay B. Thorp — 3,545,040

Douglas Reed — 3,545,040

(c) Each of the required transactions described in this Item 5(a) were reported on Forms 4 filed by Mr. Thorp filed with the Securities and Exchange Commission (the “SEC”) pursuant to Section 16 of the Act and are available on the SEC’s website at www.sec.gov, except for the following:

[insert details related to the distributions-in-kind as the final details were not reported on Forms 4]

CUSIP No. 185063 10 4

Page 18 of 20

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 4, 2023


HATTERAS VENTURE ADVISORS III, LLC

By:		/s/ Clay B. Thorp
		Manager

HATTERAS VENTURE PARTNERS III, LP

By:		Hatteras Venture Advisors III, LLC, its general partner

By:		/s/ Clay B. Thorp
		Manager

HATTERAS VENTURE AFFILIATES III, LP

By:		Hatteras Venture Advisors III, LLC, its general partner

By:		/s/ Clay B. Thorp
		Manager

HATTERAS VENTURE ADVISORS IV SBIC, LLC

By:		/s/ Clay B. Thorp
		Manager

CUSIP No. 185063 10 4

Page 19 of 20



HATTERAS VENTURE PARTNERS IV SBIC, LP

By:		Hatteras Venture Advisors IV SBIC, LLC, its general partner

By:		/s/ Clay B. Thorp
		Manager

HATTERAS VENTURE ADVISORS IV, LLC

By:		/s/ Clay B. Thorp
		Manager

HATTERAS VENTURE PARTNERS IV, LP

By:		Hatteras Venture Advisors IV, LLC, its general partner

By:		/s/ Clay B. Thorp
		Manager

HATTERAS NC FUND, LP

By:		Hatteras Venture Advisors IV, LLC, its general partner

By:		/s/ Clay B. Thorp
		Manager

*
John C. Crumpler

*
Robert A. Ingram

*
Kenneth B. Lee

CUSIP No. 185063 10 4

Page 20 of 20



*
Clay B. Thorp

*
Douglas Reed

By:		/s/ Clay B. Thorp
		Clay B. Thorp, as Attorney-in-Fact

This Amendment No. 6 to Schedule 13D was executed by Clay B. Thorp on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which was previously filed with the Reporting Person’s Schedule 13D filed with the SEC on June 17, 2016 and as amended on February 8 and April 25, 2017, March 21, 2018 and July 17 and December 4, 2019.

Get the next $CLSD alert in real time by email

Date	Price Target	Rating	Analyst
8/21/2024	$6.00	Buy	Chardan Capital Markets
6/25/2024	$5.00	Outperform	Oppenheimer
3/11/2022	$11.00 → $10.00	Market Outperform	JMP Securities
12/15/2021	$19.00 → $9.00	Outperform	Wedbush
7/29/2021	$10.00	Buy	HC Wainwright & Co.

Number of

Shares

Beneficially

Owned By

Each

Reporting

Person

with

Sole Voting Power

0

Shared Voting Power

0

Sole Dispositive Power

0

Shared Dispositive Power

0